- Thinly-traded nano cap Minerva Neurosciences (NASDAQ:NERV) is up 20% premarket (volume unknown) in response to its report of positive results from a Phase 1 trial assessing MIN-202 for the treatment on insomnia. Trial subjects with co-morbid insomnia related to major depressive disorder (MDD) experienced significant improvements in sleep onset and duration.
- The Phase 1b portion was a double-blind, placebo-controlled, randomized, four-way crossover, single dose trial involved 20 male and female patients with MDD and insomnia. The primary endpoint was latency to persistent sleep (LPS). Preliminary results showed a statistically significant effect on LPS in all three doses tested (10 mg, 20 mg and 40 mg) and prolonged sleep duration of ~45 minutes.
- MIN-202 is an orexin-2 antagonist. Its value proposition is improved safety, better restoration of sleep architecture and improved continuity compared to GABA-mimetics like Ambien (SNY).
- MIN-202 is being developed in collaboration with Janssen Pharmaceutica NV.
Minerva up premarket on trial results
Recommended For You
More Trending News
About NERV Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
NERV | - | - |
Minerva Neurosciences, Inc. |